ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
82 hedge funds and large institutions have $476M invested in Adaptimmune Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
24% less capital invested
Capital invested by funds: $624M → $476M (-$148M)
Holders
82
Holding in Top 10
–
Calls
$692K
Puts
$691K
Top Buyers
| 1 | +$4.8M | |
| 2 | +$2.66M | |
| 3 | +$2.43M | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.79M |
| 5 |
Goldman Sachs
New York
|
+$1.42M |
Top Sellers
| 1 | -$10.4M | |
| 2 | -$9.91M | |
| 3 | -$6.5M | |
| 4 |
OAMG
Odey Asset Management Group
London,
United Kingdom
|
-$2.92M |
| 5 |
Millennium Management
New York
|
-$2.92M |